SeaSpine Gains FDA Clearance for OsteoBallast DBM in Resorbable Mesh

SeaSpine continues to broaden its orthobiologic offerings, receiving FDA 510(k) clearance to market OsteoBallast™ Demineralized Bone Matrix (DBM) in Resorbable Mesh. Limited launch will occur by year-end, with full commercial launch slated for mid-2018.

OsteoBallast comprises 100% DBM with no carrier, and is designed to deliver bone graft in...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.

Contact Us